Ibrutinib CAS 936563-96-1 Purity >99.5% (HPLC) API

Ibrutinib (CAS: 936563-96-1) is an inhibitor of Bruton tyrosine kinase (BTK) for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Both MCL and CLL belong to B-cell non-Hodgkin's lymphoma, which is refractory and prone to relapse. The commonly used chemoimmunotherapy is not targeted, and grade 3 or 4 adverse reactions often occur. Ibrutinib can combine with BTK, which is necessary for the formation, differentiation, communication and survival of B lymphocytes, and irreversibly inhibit the activity of BTK, effectively inhibit the proliferation and survival of tumor cells. In addition, it is rapidly absorbed after oral administration, the maximum plasma concentration is reached 1~2h, and the adverse reactions are grade 1 or 2, which will become a new option for the treatment of CLL and MCL. On November 13, 2013, the U.S. FDA to accelerate the approved Johnson & Johnson company and the United States Imbruvica (common name: Ibrutinib) for the treatment of mantle cell lymphoma (MCL). Ibrutinib, was granted breakthrough Therapy status by the FDA in February 2013 and was approved for MCL on November 13, 2013 and CLL on February 12, 2014, respectively.